Published in Medical Letter on the CDC and FDA, March 26th, 2006
This study was a single dose, double-blind, randomized, placebo-controlled three-way crossover, human study (N=156) evaluating a Niaspan (niacin extended-release tablets) modified formulation for reduction in severity and duration of flushing, a relatively common and transient nuisance side effect for patients who take Niaspan to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.